Wu Wang

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Combination Therapy

Inflammatory Response

Angiotensin Converting Enzyme

Top Venues

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Wenli Yang, Qinghui Sun, Xiaodian Zhang, Liping Zheng, Xiaomei Yang, Na He, Yanyang Pang, Xi Wang, Zhiheng Lai, Wu-Ping Zheng, Shaoping Zheng, Wu Wang
A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy. Cell death & disease 15 (6) (2024)
Wenli Yang, Qinghui Sun, Xiaodian Zhang, Liping Zheng, Xiaomei Yang, Na He, Yanyang Pang, Xi Wang, Zhiheng Lai, Wu-Ping Zheng, Shaoping Zheng, Wu Wang
A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy. Cell death & disease 15 (6) (2024)
Wenli Yang, Qinghui Sun, Xiaodian Zhang, Liping Zheng, Xiaomei Yang, Na He, Yanyang Pang, Xi Wang, Zhiheng Lai, Wu-Ping Zheng, Shaoping Zheng, Wu Wang
A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy. Cell death & disease 15 (6) (2024)
Wenli Yang, Qinghui Sun, Xiaodian Zhang, Liping Zheng, Xiaomei Yang, Na He, Yanyang Pang, Xi Wang, Zhiheng Lai, Wu-Ping Zheng, Shaoping Zheng, Wu Wang
A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy. Cell death & disease 15 (6) (2024)
Wenli Yang, Yanyang Pang, Xi Wang, Zhiheng Lai, Yanda Lu, Shaojiang Zheng, Wu Wang
A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes. Cell death & disease 14 (7) (2023)